


REMARKS

This amendment is submitted prior to the first examination and action of the United States Patent and Trademark Office to amend the history of the application to claim benefit under 35 U.S.C. 119(e) of provisional application US Serial No. 60/327,907. No substantive changes have been made in the application and such amendments do not introduce any new matter. Applicant respectfully requests that such amendments be entered into the record.

Should the Examiner have any questions or comments concerning the before-mentioned amendments to the application or any other matter, Applicant's agent will welcome the opportunity to discuss same with the Examiner.

Respectfully submitted,



Kathryn L. Hester, Ph.D.
Registration No. 46,768
DUNLAP, CODDING & ROGERS, P.C.
9400 N. Broadway, Suite 420
Oklahoma City, Oklahoma 73114
(405) 478-5344

Agent for Applicant

MARKED UP VERSION OF PARAGRAPHS OF THE SPECIFICATION
SHOWING THE CHANGES MADE THERETO

[0001] This application claims priority under 35 U.S.C. § 119(e) of provisional U.S. Serial No. 60/256,410, filed December 18, 2000, entitled "HLA PRODUCTION FROM GENOMIC DNA," **[and]** provisional U.S. Serial No. 60/256,409, filed December 18, 2000, entitled "HLA PROTEIN PRODUCTION FROM CDNA," **and provisional U.S. Serial No. 60/327,907, filed October 9, 2001, entitled "PRODUCTION OF SOLUBLE HUMAN HLA CLASS I PROTEINS FROM GENOMIC DNA,"** the contents of which are hereby expressly incorporated in their entirety by reference.

[0063] FIG. 27 is a pictorial representation of the proposed N-proximal and C-terminal anchoring of a nonamer overlapping B*1508, B*1501, and B*1503. The shared C-terminal anchoring preferences for Tyr in the NQZHGSAEY ligand among B*1508, B*1501, and B*1503 as defined by their respective motifs (FIGS. 15 and 16) are shaded black, while the varied N-proximal anchoring preferences likewise reflected in the motifs are **[shaded gray] cross-hatched**. Ligand residues are numbered sequentially from the N terminus.